06160 and BGNE Related Headlines
Go Back- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
- BeiGene (BGNE) Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic ESCC After Prior Chemotherapy
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
- BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
- BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- BeiGene to Present at Upcoming Investor Conferences
- BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
- BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
- BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
- FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
- BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
- BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
- BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
- BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
- BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
- BeiGene to Present at the Jefferies London Healthcare Conference
- BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
- BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junctio
- BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-S
- BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
- BeiGene (BGNE) Receives Positive CHMP Opinion for BRUKINSA in Relapsed or Refractory Follicular Lymphoma
- BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
- BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
- BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
- BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
- BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
- BeiGene (BGNE), DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
- BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
- BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
- BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
- BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma
- BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
- BeiGene' (BGNE) BRUKINSA Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
- BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
- BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
- BeiGene to Present at Upcoming Investor Conferences
- The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and
- BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
- BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
- BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
- BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
06160 and BGNE Related Press Releases
Go Back- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
- BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
- BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- BeiGene to Present at Upcoming Investor Conferences
- BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
- BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
- BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
- FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
- BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
- BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
- BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
- BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
- BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
- BeiGene to Present at the Jefferies London Healthcare Conference
- BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
- BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junctio
- BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-S
- BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
- BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
- BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
- BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
- BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
- BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
- BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
- BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
- BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
- BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma
- BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
- BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
- BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
- BeiGene to Present at Upcoming Investor Conferences
- The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and
- BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
- BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
- BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
- BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
